New combination treatment authorized for unresectable urothelial cancer patients
Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate ) in combination with KEYTRUDA® (pembrolizumab,…